Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699547 | 0.83 | MEN1 (0.48) | SMN1; SMN2MAPTRAB9ANPC1HTT | |
| SCHEMBL3931721 | 0.81 | HPGD (0.57) | SMN1; SMN2MAPTHPGDRAB9ANPC1 | |
| SCHEMBL13890768 | 0.79 | L3MBTL1 (0.55) | MAPTRAB9ANPC1HTTMEN1 | |
| SCHEMBL2310611 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTHPGDRAB9ANPC1 | |
| SCHEMBL3930649 | 0.77 | MAPT (0.66) | SMN1; SMN2MAPTRAB9ANPC1HTT | |
| SCHEMBL11956747 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTHPGDRAB9ANPC1 | |
| SCHEMBL22279637 | 0.75 | TNIK (0.52) | SMN1; SMN2MAPTHPGDMEN1KMT2A | |
| SCHEMBL3936393 | 0.75 | KMT2A (0.58) | SMN1; SMN2MAPTRAB9ANPC1HTT | |
| SCHEMBL3931647 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTHPGDRAB9ANPC1 | |
| SCHEMBL17813317 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTHPGDRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-7501447-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | SMN1; SMN2 529/4885MAPT 2921/4885HPGD 501/4885 |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | H1-3, H1-4, CYP3A4 | SMN1; SMN2 1517/4885MAPT 3719/4885HPGD 1859/4885 |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | CYP3A4, CYP2C19, H1-3 | SMN1; SMN2 1204/4885MAPT 3678/4885HPGD 1510/4885 |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | TBXA2R, CYP2C19, CYP3A43 | SMN1; SMN2 1400/4885MAPT 3764/4885HPGD 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.